Amylyx launches USD 350 million follow-on common stock offering - AMLX News | RalliesAmylyx launches USD 350 million follow-on common stock offering
A
AMLX• Follow-on offering and intended use of proceeds
- Amylyx launched an underwritten public offering of USD 350 million of common stock.
- Underwriters hold a 30-day option to buy up to an additional USD 52.5 million of shares.
- Proceeds earmarked for avexitide pre-commercial work, research and development, working capital, and general corporate purposes.
- Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital were named joint bookrunners.
•
